Contract research organizations (CROs) are hot targets this year. The heavy demand by pharma and biotech companies is attracting large private equity buyers.
The CRO market is a favorite of private equity investors, and M&A activity has been strong in the first half of 2017.
The Rehabilitation sector is still fairly fragmented, but consolidation is coming. Some 40 deals have been announced in 2016, a 21% increase compared with 2015’s then-record of 33 deals. This year saw a ramp-up in the number of deals announced by REITs and private equity firms, too.